References
- 1. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, el al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004; 304:554.
- 2. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009; 9:550-62.10.1038/nrc2664
- 3. Hernandez-Aya LF, Gonzalez-Angulo AM.Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer. Oncologist. 2011; 16:404-14.10.1634/theoncologist.2010-0402
- 4. Andersen JN, Sathyanarayanan S, Di Bacco A, Chi A, Zhang T, Chen AH, et al. Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors. Sci Transl Med. 2010; 2:43ra55.10.1126/scitranslmed.3001065
- 5. Bedard PL, Cardoso F, Piccart-Gebhart MJ. Stemming resistance to HER-2 targeted therapy. J Mammary Gland Biol Neoplasia. 2009; 14:55-66.10.1007/s10911-009-9116-x
- 6. Kolasa IK, Rembiszewska A, Felisiak A, Ziolkowska- Seta I, Murawska M, Moes J, et al. PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients. Cancer Biol Ther. 2009; 8:21-6.
- 7. Coughlin CM, Johnston DS, Strahs A, Burczynski ME, Bacus S, Hill J, et al. Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy. Breast Cancer Res Treat. 2010; 124:1-11.
- 8. Moulder SL.Does the PI3K pathway play a role in basal breast cancer? Clin Breast Cancer. 2010; 10 Suppl 3: S66-71.10.3816/CBC.2010.s.014